Literature DB >> 9012641

Apolipoprotein A-IFin. Dominantly inherited hypoalphalipoproteinemia due to a single base substitution in the apolipoprotein A-I gene.

H E Miettinen1, H Gylling, T A Miettinen, J Viikari, L Paulin, K Kontula.   

Abstract

We have identified a large kindred with severe serum HDL cholesterol deficiency. The proband, a 65-year-old woman, had greatly diminished concentrations of serum HDL cholesterol (0.19 mmol/L) and apolipoprotein (apo) A-I (21.9 mg/dL). HDL cholesterol and apo A-I levels were similarly reduced in all affected family members, while apo A-II levels were about half of those in the nonaffected family members. Pedigree analysis suggested a dominant inheritance pattern of the phenotype. Sequence analysis of the exons and exon-intron boundaries of the apo A-I gene revealed heterozygosity for a single T-to-G point mutation substituting arginine for leucine at residue 159 of the mature apo A-I protein (apo A-IFin). The T-to-G substitution destroys an Fsp I cleavage site, permitting direct polymerase chain reaction/restriction enzyme analysis of the mutation. All the affected family members were shown to be heterozygous for the apo A-IFin mutation. Isoelectric focusing revealed the presence of the mutant apo A-IFin protein in both serum and HDL of the affected subjects. Functional consequences of the mutation were examined by expressing the mutated and wild-type apo A-I cDNAs in COS-7 cells. The mutant apo A-I mRNA had a size similar to that of the normal mRNA, and both mutant and wild-type apo A-I proteins were secreted into the cell media. In vivo kinetic studies of apo A-I revealed increased catabolism in affected subjects. In conclusion, we describe a novel point mutation of the apo A-I gene, apo A-IFin, causing a dominantly negative phenotype as regards serum HDL levels, possibly due to increased catabolism of apo A-I.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9012641     DOI: 10.1161/01.atv.17.1.83

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  7 in total

1.  Dysfunctional HDL containing L159R ApoA-I leads to exacerbation of atherosclerosis in hyperlipidemic mice.

Authors:  Mary G Sorci-Thomas; Manal Zabalawi; Manish S Bharadwaj; Ashley J Wilhelm; John S Owen; Bela F Asztalos; Shaila Bhat; Michael J Thomas
Journal:  Biochim Biophys Acta       Date:  2011-09-14

2.  Molecular etiology of a dominant form of type III hyperlipoproteinemia caused by R142C substitution in apoE4.

Authors:  Alexander M Vezeridis; Konstantinos Drosatos; Vassilis I Zannis
Journal:  J Lipid Res       Date:  2010-09-22       Impact factor: 5.922

3.  Alteration of negatively charged residues in the 89 to 99 domain of apoA-I affects lipid homeostasis and maturation of HDL.

Authors:  Andreas K Kateifides; Irina N Gorshkova; Adelina Duka; Angeliki Chroni; Dimitris Kardassis; Vassilis I Zannis
Journal:  J Lipid Res       Date:  2011-04-19       Impact factor: 5.922

4.  apoE3[K146N/R147W] acts as a dominant negative apoE form that prevents remnant clearance and inhibits the biogenesis of HDL.

Authors:  Panagiotis Fotakis; Alexander Vezeridis; Ioannis Dafnis; Angeliki Chroni; Dimitris Kardassis; Vassilis I Zannis
Journal:  J Lipid Res       Date:  2014-04-28       Impact factor: 5.922

5.  ApoA-IV promotes the biogenesis of apoA-IV-containing HDL particles with the participation of ABCA1 and LCAT.

Authors:  Adelina Duka; Panagiotis Fotakis; Dimitra Georgiadou; Andreas Kateifides; Kalliopi Tzavlaki; Leonard von Eckardstein; Efstratios Stratikos; Dimitris Kardassis; Vassilis I Zannis
Journal:  J Lipid Res       Date:  2012-11-06       Impact factor: 5.922

6.  Plant sterols: factors affecting their efficacy and safety as functional food ingredients.

Authors:  Alvin Berger; Peter J H Jones; Suhad S Abumweis
Journal:  Lipids Health Dis       Date:  2004-04-07       Impact factor: 3.876

Review 7.  Structural Insights into High Density Lipoprotein: Old Models and New Facts.

Authors:  Valentin Gogonea
Journal:  Front Pharmacol       Date:  2016-01-12       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.